René Lardenoije

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The last decade has seen a dramatic rise in the development of new cellular therapeutics in a wide range of indications. There have been acceptable safety profiles reported in early studies using blood-derived and adherent stem cell products, but also an inconsistent efficacy record. Further expansion has been hindered in part by a lack of capital (both(More)
  • 1